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Abstract— A benzhydryl tropinone oxime that is potently toxic to Trypanosoma cruzi has been previously identified. An SAR 
investigation determined that no part of the original compound was superfluous and all early SAR probes led to significant drops in 
activity. The only alteration that could be achieved without loss of activity was replacement of the aryl chloride substituent with chloro 
homologues. This led to the discovery of a trifluoromethyl-containing analogue with an EC50 against T. cruzi of 30 nM and a cytotoxicity 
selectivity index of over 1000 relative to rat skeletal myoblast L-6 cells. 
Type your abstract here. It should be no longer than 3–4 lines. [BMCL ABSTRACT] ©2000 Elsevier Science Ltd. All rights reserved. 
The protozoan parasite T. cruzi is the causative agent of 
Chagas  disease  which  is  found  in  18  countries  in  Latin 
America. In the 2004 World Health Report
1 Chagas disease 
was estimated to cause 14 thousand deaths and a disease 
burden of 0.7 million DALYs annually. There are currently 
only  two  significant  therapies  for  Chagas  disease, 
nifurtimox  and  benznidazole  (Figure  1).
2  These  drug 
treatments  are  ineffective  at  preventing  the  development 
and  treatment  of  chronic  Chagas  disease
3  and  induce  a 
number of adverse effects. Hence, there is an urgent need 
for the development of new cost effective therapy against 
T. cruzi with minimal side effects. 
 
 
Figure 1. Current T. cruzi therapies 
 
We  have  previously  reported  on  a  high-throughput 
screening  campaign  conducted  to  identify  inhibitors  of 
trypanothione reductase (TR) that might consequently be 
toxic to trypanosomatids.
4,5 Amongst the identified hits was 
a  benzhydryl  tropinone  oxime  that  was  found  to  be 
potently toxic towards T. cruzi with an EC50 of 110 nM and 
highly  selective  for  this  organism  relative  to  other 
trypanosomatids  such  as  Leishmania  donovani  and 
Trypanosoma  brucei.
5  These  data  are  summarized  in 
Figure 2. 
 
 
Assay  EC50 (mM) 
TR (T.cruzi)  35
a 
P.falciparum  7.5
b 
L.donovani  >30
c 
T.cruzi  0.11
d 
T.brucei  3
e 
Cytotoxicity  36
f 
 
a  Recombinant  trypanothione  reductase,  Trypanosoma cruzi Brazilian 
Silvio strain, X10/1.   
b Plasmodium falciparum 3D7 strain, erythrocylic stage, chloroquine was 
used as a control, EC50 9.4 nM. 
c  Leishmania  donovani  MHOM/ET/67/L82  strain,  amastigote  stage, 
miltefosine was used as a control, EC50 0.27 µM. 
d  Trypanosoma  cruzi  Tulahaen  C2C4  strain,  amastigote  stage, 
benznidazole was used as a control, EC50 1.8 µM. 
e Trypanosoma brucei rhodesiense strain STIB 900, bloodstream form.  
Melarsoprol (EC50 17 nM) was used as a control. 
f Rat skeletal myoblast cell L-6 strain, podophyllotoxin was used as a 
control, EC50 14 nM.  
 
Figure 2. Structure and antiparasitic activity of benzhydryl 
tropinone oxime 1. 
 
For several reasons, significantly amongst these being the 
very  weak  trypanothione  reductase  inhibitory  activity  of 
compound 1 (EC50 35uM, Figure 2), we have previously 
argued  that  the  observed  potent  T.cruzi-selective 
trypanocidal  activity  could  likely  be  due  to  off-target ACCEPTED MANUSCRIPT 
 
activity.
5    Subsequently,  we  gained  access  to  a  higher 
throughput  parasite  assay  and  it  was  principally  for  this 
reason that we initiated a hit optimisation campaign around 
compound 1, using a whole parasite primary assay.  This 
communication  will  disclose  the  results  of  our  SAR 
investigation into this compound. 
 
Two main synthetic methods were utilised (Figure 3).  One 
method enabled rapid analogue production of the tropane 
portion  of  1  by  reaction  of  a  biaryl  oxylamine  with  an 
appropriate ketone. The biaryl oxylamine was synthesised 
Figure  3.  Benzhydryl  tropane  oxime  synthesis.  See 
Supplementary. 
 
via  deprotection  of  the  corresponding 
benzhydryloxyphthalimide
6 which in turn was synthesised 
from the biaryl alcohol, either directly through a Mitsunobu 
reaction
6 or via its corresponding chloride.
7,8 The second 
method  enabled  rapid  analogue  production  of  the 
benzhydryl  portion,  through  reaction  of  the  tropinone 
oxime  with  an  appropriate  arylmethyl  chloride.    Results 
from  the  whole  cell  T.cruzi  assay  of  the  first  set  of 
compounds (Figure 4) confirmed that two aryl groups were 
 
Struct  EC50 (mM)  Cmpds 
 
R
1  R
2 
T.cruzi
a  Cytotox
b 
1  A  Cl  Ph  0.07  15 
2  A  Cl  H  >10  >100 
3  A  H  H  >10  >100 
4  B  cyclohexyl  -  >10  >100 
5  B  CMe2  -  >10  >100 
6  B  des-Me tropane   -  2.0  9.8 
7  B  4-(N-Me piperidine)  -  3.7  50 
a  Trypanosoma  cruzi  Tulahaen  C2C4  strain,  amastigote  stage, 
benznidazole was used as a control, EC50 1.8 µM. 
b Rat skeletal myoblast cell L-6 strain, podophyllotoxin was used as a 
control, EC50 14 nM.  
 
Figure  4.  Benzhydryl  tropane  oxime  SAR:  deletion 
analogues 
 
essential for activity and removal of one of the phenyl rings 
(2, 3) resulted in loss of activity.  It was also determined 
that  the  basic  nitrogen  atom  in  the  tropane  ring  was 
important, as replacement with cycloalkyl (4) or alkyl (5) 
resulted in complete loss of activity.  Even removal of the 
N-methyl  group  (6)  or  the  tropane  bridge  (7)  led  to 
significant loss of activity. 
 
Having  established  that  the  tropane  ring  and  two  aryl 
groups  are  important,  a  second  set  of  compounds  was 
assembled to investigate changes in aryl ring connectivity.  
Replacing the unsubstituted phenyl ring with a pyridine or 
thiazole led to a significant loss in activity (8 - 13, Figure 
5),  though  to  greatly  varying  extents,  as  the  4-pyridyl 
analogue  10  was  twelve  times  weaker  again  than  the  3-
pyridyl analogue 9. Similarly, introducing a carbon chain 
between the two phenyl rings on either side led to variable 
losses in activity (14 - 18), and constraining the rings (19) 
led to complete loss of activity. 
 
 
 
Struct  EC50 (mM)  Cmpds 
 
R 
T.cruzi
a  Cytotox
b 
8  A  2-pyridine  2.9  >100 
9  A  3-pyridine  0.5  >100 
10  A  4-pyridine  6.2  >100 
11  A  2-thiazole  2.3  >100 
12  A  4-thiazole  0.8  71 
13  A  5-thiazole  6.0  >100 
    n1
  n2
   
14  B  0  1  2.1  40 
15  B  0  2  6.5  20 
16  B  0  3  4.3  17 
17  B  1  0  1.9  49 
18  B  2  0  0.8  16 
19  C  -  -  >10  68 
a  Trypanosoma  cruzi  Tulahaen  C2C4  strain,  amastigote  stage, 
benznidazole was used as a control, EC50 1.8 µM. 
b Rat skeletal myoblast cell L-6 strain, podophyllotoxin was used as a 
control, EC50 14 nM.  
 
Figure 5. SAR probing of the benzhydryl group. 
 
This tight SAR suggested that the benzhydryl group should 
be  retained  for  optimum  activity.  Therefore,  by  way  of 
finer  SAR probing, a series of compounds with electron 
withdrawing and donating groups in different positions on 
the  benzhydryl  phenyl  rings  were  synthesised  (20  -  28, 
Figure  6).  These  compounds  all  lost  significant  activity, 
except  the  p-methoxy  compound  (24)  which  retained 
reasonable activity with an EC50 of 300 nM. We similarly 
investigated fine alterations of the tropane ring, namely by 
extension  of  the  N-alkyl  substituent.    As  shown  for ACCEPTED MANUSCRIPT 
 
compounds  27  and  28,  significant  loss  of  activity  was 
observed  for  the  tropane  N-hydroxyethyl  and  N-
(dimethylamino)ethyl substituents respectively. 
 
 
 
EC50 (mM)  Cmpds  R
1  R
2  R
3 
T.cruzi
a  Cytotox
b 
1  4-Cl  H  Me  0.07  15 
20  3-Cl  H  Me  2.1  19 
21  2-Cl  H  Me  6.8  15 
22  4-Cl  4-Cl  Me  6.0  16 
23  H  H  Me  1.3  >100 
24  4-OMe  H  Me  0.3  >100 
25  3-OMe  H  Me  2.0  48 
26  2-OMe  H  Me  >10  >100 
27  4-Cl  H  CH2CH2OH  7.8  47 
28  4-Cl  H  CH2CH2NMe2  6.9  15 
a  Trypanosoma  cruzi  Tulahaen  C2C4  strain,  amastigote  stage, 
benznidazole was used as a control, EC50 1.8 µM. 
b Rat skeletal myoblast cell L-6 strain, podophyllotoxin was used as a 
control, EC50 14 nM.  
 
Figure 6. Benzhydryl and tropane substituent SAR. 
 
Thus far, no improvement in the activity of the initial hit 1 
had been obtained, suggesting that all structural aspects of 
this compound were important for biological activity.  With 
this  information  in  hand,  a  final  set  of  very  fine  SAR 
probes  was  assembled,  where  the  chlorine  atom  was 
replaced  with  homologues.    These  results  are  shown  in 
Figure  7.  Gratifyingly,  good  activity  was  consistently 
observed and in three cases was better than the original hit.  
Thus  the  bromo  (30),  iodo  (31)  and  trifluoromethyl 
compounds (34) displayed outstanding activity with whole 
organism  EC50  values  of  40  nM,  40  nM  and  30  nM 
respectively.  The weaker activity for the fluoro, methyl 
 
 
 
 
 
 
 
 
 
aTrypanosoma  cruzi  Tulahaen  C2C4  strain,  amastigote  stage, 
benznidazole was used as a control, EC50 1.8 µM. 
b Rat skeletal myoblast cell L-6 strain, podophyllotoxin was used as a 
control, EC50 14 nM.  
 
Figure 7. Chloro homolog SAR. 
 
and cyano-containing analogues suggests a combination of 
electronegativity  but  principally  hydrophobicity  is 
important for most potent activity 
 
In  summary,  we  have  described  a  series  of  potent 
trypanocides,  benzhydryl  tropinone  oximes,  that  do  not 
tolerate variation to the structure apart from substitution of 
the  chloro-aryl  substituent  by  other  hydrophobic 
electronegative  substituents.  Compound  34,  where  the 
chlorine atom is replaced by a trifluoromethyl group, has 
an  EC50  against  T.  cruzi  of  30  nM  with  cytotoxicity  to 
mammalian cells more than 1000-fold weaker. 
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EC50 (mM)  Cmpds  R
 
T.cruzi
a  Cytotox
b 
1  Cl  0.07  15 
29  F  0.8  50 
30  Br  0.04  40 
31  I  0.04  39 
32  Me  0.3  51 
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